Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2012 / Cilt: 21 - Sayı: 3

Primidone usage as a rare cause of drug-induced hyperkalemia

İlaca bağlı hiperkaleminin nadir bir nedeni olarak primidon kullanımı

Pages
316–318
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Irregular distribution of potassium between the intracellular and extracellular space and imbalance between intake and excretion are the main factors in hyperkalemia pathogenesis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hyperkalemia is a life-threatening electrolyte disorder.
📊
Key Findings & Data:Elderly patients are more prone to developing hyperkalemia due to age-related decline in glomerular fi ltration rate.An 81-year-old female patient previously diagnosed as having diabetes mellitus, hypertension and chronic kidney disease who was on amlodipine and basal insulin therapy, was administered primidone 31.25 mg/day orally for the treatment of essential tremor.
💡
Conclusion & Impact:Irregular distribution of potassium between the intracellular and extracellular space and imbalance between intake and excretion are the main factors in hyperkalemia pathogenesis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hyperkalemia is a life-threatening electrolyte disorder. Elderly patients are more prone to developing hyperkalemia due to age-related decline in glomerular fi ltration rate.An 81-year-old female patient previously diagnosed as having diabetes mellitus, hypertension and chronic kidney disease who was on amlodipine and basal insulin therapy, was administered primidone 31.25 mg/day orally for the treatment of essential tremor. After 2 days, serum potassium increased to 7.6 mEq/L from the baseline level of 5.3. Urinary potasium level was 11.4 mEq/L, and transtubular potasium gradient (TTKG) 2.1%. Since no predisposing factor for hyperkalemia could be detected, primidone was discontinued. After 7 days, the serum potassium level returned to normal. Irregular distribution of potassium between the intracellular and extracellular space and imbalance between intake and excretion are the main factors in hyperkalemia pathogenesis. A TTKG value

Özet

Hiperkalemi yaşamı tehdit eden ciddi bir elektrolit bozukluğudur. Yaşa bağlı glomerüler fi ltrasyon hızında azalmadan dolayı yaşlılar hiperkalemiye daha yatkındır.Diabetes mellitus, hipertansiyon ve kronik böbrek hastalığı bulunan, amlodipin ile bazal insülin kullanan 81 yaşındaki kadın hastaya esansiyel tremor nedeniyle primidon 250 mg 1/8 tb başlandı. İlaç başlandıktan 2 gün sonra serum potasyum değeri 5,3 mEq/L'den 7,6 mEq/L'ye yükseldi. İdrar potasyum düzeyi:11,4 mEq/L, transtübüler potasyum değişkenliği (TTPD) %2.1 saptandı. Hiperkalemiye neden olabilecek yeni gelişen bir faktör bulunamaması nedeniyle hastaya başlanan primidon kesildi. İlaç kesildikten 7 gün sonra serum potasyum düzeyi normale döndü. Hiperkalemi patogenezinde başlıca hücre içi ve dışı potasyum dağılım düzensizliği ile potasyum alım ve atılım dengesizliği rol oynamaktadır. TTPD'nin %5'in altında olması aldosteron eksikliği ya da etkisizliğini düşündürür. Olgumuzda TTPD'in düşük bulunması ilaca bağlı gelişen mineralokortikoid aktivite yetersizliğini düşündürmektedir. Yaşlı ve potasyum yüksekliğine neden olabilecek eşlik eden hastalığı bulunan ya da serum potasyum değeri sınırda olan hastalarda, yeni gelişen hiperkaleminin etiyolojisinde primidon gibi hiperkalemi yapıcı etkisi iyi bilinmeyen ilaçların neden olabileceği akılda tutulmalıdır.

🔖

Cite This Article

ESER, B., AYLI, M. D., YAYAR, Ö., ERDOĞAN, B., ERCAN, Z., BÜYÜKBAKKAL, M., MERHAMETSİZ, Ö., KUTLUGÜN, A., AKOĞLU, H. (2022). Primidone usage as a rare cause of drug-induced hyperkalemia. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 21 - Sayı: 3, 316–318. https://ajindex.com/articles/636381

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Michelis MH: Hyperkalemia in the elderly. Am J Kidney Dis 1990; 16: 296-299 2. Brodie MJ, French JA: Management of epilepsy in adolescents and adults. Lancet 2000; 356: 323-329 3. Lehnhardt A, Kemper MJ: Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol 2011; 26: 377-384 4. Perazella MA: Drug-induced hyperkalemia: Old culprits and new offenders. Am J Med 2000; 109: 307-314 5. Schambelan M, Sebastian A, Biglieri EG: Prevalence, pathogenesis and functional signifi cance of aldosterone defi ciency in hyperkalemic patients with chronic renal insuffi ciency. Kidney Int 1980; 17: 89-101 6. Batlle DC, Arruda JA, Kurtzman NA: Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. N Engl J Med 1981; 304: 373-380 7. DeFronzo RA: Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 1980; 17: 118-134 8. Rose BD, Post TW: Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, New York: McGraw-Hill, 2001, 900-901 9. eHealthMe - Real World Drug Outcomes. http://www.ehealthme. com/ ds/primidone/hyperkalemia. 2012/04/02 10. Weir MR, Rolfe M: Potassium homeostasis and Renin- Angiotensin- Aldosterone system inhibitors. Clin J Am Soc Nephrol 2010; 5: 531-548 11. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T: ILAE treatment guidelines: Evidence based analysis of antiepileptic drug effi cacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094-1120